SBC Medical Group Positions for Growth Through Expansion and Strategic Initiatives

SBC Medical Group Holdings Inc. (NASDAQ: SBC) pursued a year of strategic growth in 2025, focusing on expanding clinic accessibility and differentiating its services with advanced treatments and competitive pricing. The company increased its franchise locations by 15% year-over-year to 258 clinics as of September 30, 2025, while revised pricing strategies boosted average revenue per customer by 5% in the third quarter. This growth was supported by a multi-brand approach that attracted higher revenue-generating customers and maintained a 72% repeat business rate.

The company expanded its service offerings to include plastic surgery and infertility treatments while launching new brands like "Neo Skin Clinic" and "Hada no Aozora Clinic" in Tokyo. Strategic acquisitions played a crucial role in SBC's expansion, including the purchase of MB Career Lounge Co. Ltd., a management support provider for medical institutions, and the acquisition of subsidiary Waqoo to enhance research and development in clinical areas such as AGA and orthopedics. These moves strengthened SBC's competitive position in Japan's fragmented aesthetics market, where the company employs over 500 licensed doctors across its network.

Financial performance showed significant improvement, with SBC reporting a return to more typical cost structures following its IPO. The company's average revenue per visit reached $298 in the third quarter, representing an 8.4% increase from the first quarter of 2025. This financial strength was further validated by SBC's inclusion in the Russell 3000® Index, which according to the company, benchmarks approximately $10.6 trillion in assets in the United States alone through FTSE Russell indexes. This inclusion increases visibility among institutional and individual investors who utilize index funds and ETFs.

International expansion formed a key component of SBC's growth strategy, with the company entering Singapore and Thailand markets while announcing plans for U.S. expansion in early 2026. In Singapore, SBC expanded its collaboration with Aesthetic Healthcare Holdings Pte. Ltd., which it acquired in 2024. The company also signed an e-consulting agreement with BLEZ ASIA Co. Ltd., which operates more than 20 pharmacies and clinics in Thailand, to provide management support for a new dermatology clinic in Bangkok. These international moves position SBC to capitalize on cosmetic tourism, particularly from Chinese consumers drawn to Japan's reputation for advanced techniques and qualified medical staff.

To support this international growth, SBC has implemented Chinese-language customer service initiatives, developed country-specific applications, and conducted marketing events in Shanghai. The company's strategic positioning comes as the global cosmetic surgery and procedure market, valued at $122.08 billion in 2022, continues to grow at a compound annual rate of 14.7% through 2030. With $125 million in cash at the beginning of the year and a $5 million stock buyback program demonstrating confidence in its valuation, SBC Medical Group has established a foundation for continued expansion in 2026 and beyond.